DOI QR코드

DOI QR Code

Treatment of Metastatic Colorectal Cancer With or Without Bevacizumab: Can the Neutrophil/Lymphocyte Ratio Predict the Efficiency of Bevacizumab?

  • Dirican, Ahmet (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) ;
  • Varol, Umut (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) ;
  • Kucukzeybek, Yuksel (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) ;
  • Alacacioglu, Ahmet (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) ;
  • Erten, Cigdem (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) ;
  • Somali, Isil (Department of Medical Oncology, Institute of Oncology, Dokuz Eylul University) ;
  • Can, Alper (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) ;
  • Demir, Lutfiye (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) ;
  • Bayoglu, Ibrahim Vedat (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) ;
  • Akyol, Murat (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) ;
  • Yildiz, Yasar (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) ;
  • Koyuncu, Betul (Department of Internal Medicine, Izmir Katip Celebi University Ataturk Training and Research Hospital) ;
  • Coban, Eyup (Department of Internal Medicine, Izmir Katip Celebi University Ataturk Training and Research Hospital) ;
  • Tarhan, Mustafa Oktay (Department of Medical Oncology, Institute of Oncology, Dokuz Eylul University)
  • Published : 2014.06.30

Abstract

Background: The purpose of this study was to analyze the predictive value of neutrophil/lymphocyte ratio (NLR) to better clarify which patient groups will benefit the most from particular treatments like bevacizumab. Materials and Methods: A total of 245 treatment-naive metastatic colorectal cancern (mCRC) patients were retrospectively enrolled and divided into 2 groups: 145 group A patients were treated with chemotherapy in combination with bevacizumab, and 100 group B patients were treated as above without bevacizumab. Results: Group A patients had better median overall survival (OS) and progression-free survival (PFS) (24.0 and 9.0 months) than group B patients (20 and 6.0 months) (p=0.033; p=0.015). In patients with low NLR, OS and PFS were significantly longer in group A patients (27 vs 18 months, p=0.001; 11 vs 7 months, p=0.017). Conclusions: We conclude that NLR, a basal cancer related inflammation marker, is associated with the resistance to bevacizumab-based treatments in mCRC patients.

References

  1. Saltz LB, Clarke S, Diaz-Rubio E, et al (2008). Bevacizumab in combination with oxaliplatin-based chemotherapy as firstline therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol, 26, 2013-9 https://doi.org/10.1200/JCO.2007.14.9930
  2. Stathopoulos GP, Batziou C, Trafalis D, et al (2010). Treatment of colorectal cancer with and without bevacizumab: a phase III study. Oncology, 78, 376-81. https://doi.org/10.1159/000320520
  3. Unal D, Eroglu C, Kurtul N, Oguz A, Tasdemir A (2013). Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pac J Cancer Prev, 14, 5237-42. https://doi.org/10.7314/APJCP.2013.14.9.5237
  4. Uygun K, Bilici A, Kaya S, et al (2013). XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions. Asian Pac J Cancer Prev, 14, 2283-8. https://doi.org/10.7314/APJCP.2013.14.4.2283
  5. Van Cutsem E, Rivera F, Berry S, et al (2009). First BEAT investigators. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol, 20, 1842-7. https://doi.org/10.1093/annonc/mdp233
  6. Wang S, Zhang Z, Fang F, et al (2011). The neutrophil/lymphocyte ratio is an independent prognostic indicator in patients with bone metastasis. Oncol Lett, 2, 735-740. https://doi.org/10.3892/ol.2011.304
  7. Zheng YB, Zhao W, Liu B, et al (2013). The blood neutrophil-tolymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib. Asian Pac J Cancer Prev, 14, 5527-31. https://doi.org/10.7314/APJCP.2013.14.9.5527
  8. Macedo LT, da Costa Lima AB, Sasse AD, et al (2012). Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups. BMC Cancer, 13, 89.
  9. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol, 23, 3697-705.
  10. Kacan T, Babacan NA, Seker M, et al (2014). Could the neutrophil to lymphocyte ratio be a poor prognostic factor for non small cell lung cancers? Asian Pac J Cancer Prev, 15, 2089-94. https://doi.org/10.7314/APJCP.2014.15.5.2089
  11. Kemal Y, Yucel I, Ekiz K, et al (2014). Elevated serum neutrophil to lymphocyte and platelet to lymphocyte ratios could be useful in lung cancer diagnosis. Asian Pac J Cancer Prev, 15, 2651-4. https://doi.org/10.7314/APJCP.2014.15.6.2651
  12. Ozdemir Y, Akin ML, Sucullu I, Balta AZ, Yucel E (2014). Pretreatment neutrophil/lymphocyte ratio as a prognostic aid in colorectal cancer. Asian Pac J Cancer Prev, 15, 2647-50. https://doi.org/10.7314/APJCP.2014.15.6.2647
  13. Pectasides D, Papaxoinis G, Kalogeras KT, et al (2012). XELIRIbevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis. BMC Cancer, 12, 271. https://doi.org/10.1186/1471-2407-12-271
  14. Price TJ, Zannino D, Wilson K, et al (2012). Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of capecitabine, bevacizumab and mitomycin C. Ann Oncol, 23, 1531-6. https://doi.org/10.1093/annonc/mdr488
  15. Proctor MJ, McMillan DC, Morrison DS, et al (2012). A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer, 107, 695-9. https://doi.org/10.1038/bjc.2012.292
  16. Gyanchandani R, Sano D, Ortega Alves MV, et al (2013). Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma. Oral Oncol, 49, 761-70. https://doi.org/10.1016/j.oraloncology.2013.03.452
  17. Fuchs CS, Marshall J, Barrueco J, et al (2008). Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol, 26, 689-90. https://doi.org/10.1200/JCO.2007.15.5390
  18. Giantonio BJ, Catalano PJ, Meropol NJ, et al (2007). Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol, 25, 1539-44. https://doi.org/10.1200/JCO.2006.09.6305
  19. Gunduz S, Mutlu H, Uysal M, Coskun HS, Bozcuk H (2014). Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors. Asian Pac J Cancer Prev, 15, 3801-4. https://doi.org/10.7314/APJCP.2014.15.8.3801
  20. Hurwitz HI, Fehrenbacher L, Novotny W, et al (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 350, 2335-42. https://doi.org/10.1056/NEJMoa032691
  21. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al (2005). Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol, 23, 3502-8 https://doi.org/10.1200/JCO.2005.10.017
  22. Hochster HS, Hart LL, Ramanathan RK, et al (2008). Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol, 26, 3523-9. https://doi.org/10.1200/JCO.2007.15.4138
  23. Ishizuka M, Nagata H, Takagi K, et al (2012). Clinical significance of tumor pathology for postoperative survival of patients undergoing surgery for stage IV colorectal cancer. Anticancer Res, 32, 3291-7.
  24. De Gramont A, Figer A, Seymour M, et al (2000). Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol, 18, 2938-47. https://doi.org/10.1200/JCO.2000.18.16.2938
  25. Cedres S, Torrejon D, Martinez A, et al (2012). Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol, 14, 864-9. https://doi.org/10.1007/s12094-012-0872-5
  26. Cihan YB, Ozturk A, Mutlu H (2014). Relationship between prognosis and neutrophil: lymphocyte and platelet:lymphocyte ratios in patients with malignant pleural mesotheliomas. Asian Pac J Cancer Prev, 15, 2061-7. https://doi.org/10.7314/APJCP.2014.15.5.2061
  27. Clarke S, Burge M, Cordwell C, et al (2013). An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab $(Avastin^{TM})$. BMC Cancer, 13, 120. https://doi.org/10.1186/1471-2407-13-120
  28. Ducreux J, Bennouna M, Hebbar M, et al (2007). Efficacy and safety findings from a randomized phase III study of capecitabine and oxaliplatin vs infusion 5-FU/LV+O (FOLFOX-6) for metastatic colorectal cancer (MCRC) (abstract). J Clin Oncol, 25, 170.
  29. Eisenhauer EA, Therasse P, Bogaerts J, et al (2009).New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228-47. https://doi.org/10.1016/j.ejca.2008.10.026
  30. Ferrara N, Kerbel RS (2005). Angiogenesis as a therapeutic target. Nature, 438, 967-74. https://doi.org/10.1038/nature04483
  31. Formica V, Massara MC, Portarena I, et al (2009). Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients. Cancer Biomark, 5, 167-75. https://doi.org/10.3233/CBM-2009-0101
  32. Fuchs CS, Marshall J, Mitchell E, et al (2007). Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol, 25, 4779-86. https://doi.org/10.1200/JCO.2007.11.3357
  33. Abajo A, Boni V, Lopez I, et al (2012). Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients. Br J Cancer, 107, 287-90. https://doi.org/10.1038/bjc.2012.242
  34. Algire GH, Chalkley HW, Legallais FY, Park HD (1945). Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst, 6, 73-85. https://doi.org/10.1093/jnci/6.1.73
  35. Botta C, Barbieri V, Ciliberto D, et al (2013). Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Cancer Biol Ther, 14, 469-75. https://doi.org/10.4161/cbt.24425

Cited by

  1. Mean Platelet Volume as a Prognostic Marker in Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Combined Chemotherapy vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6421
  2. Efficacy and Safety of Bevacizumab in Chinese Patients with Metastatic Colorectal Cancer vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6559
  3. Myeloid-Derived Suppressor Cells in Multiple Myeloma: Pre-Clinical Research and Translational Opportunities vol.4, pp.2234-943X, 2014, https://doi.org/10.3389/fonc.2014.00348
  4. Endothelial Cell Proliferation and Vascular Endothelial Growth Factor Expression in Primary Colorectal Cancer and Corresponding Liver Metastases vol.16, pp.11, 2015, https://doi.org/10.7314/APJCP.2015.16.11.4549
  5. Diet and Colorectal Cancer Risk in Asia - a Systematic Review vol.16, pp.13, 2015, https://doi.org/10.7314/APJCP.2015.16.13.5389
  6. Analyses of Multiple Factors for Determination of "Selected Patients" Who Should Receive Rechallenge Treatment in Metastatic Colorectal Cancer: a Retrospective Study from Turkey vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2833
  7. Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab vol.48, pp.2, 2017, https://doi.org/10.1007/s12029-016-9879-4
  8. Real-world use of bevacizumab in metastatic colorectal, metastatic breast, advanced ovarian and cervical cancer: a systematic literature review pp.1744-8301, 2018, https://doi.org/10.2217/fon-2018-0480
  9. Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway vol.19, pp.4, 2018, https://doi.org/10.3390/ijms19041232